[Correction of hyperdyslipidemia using polyene-structure substances. Controlled clinical trial].
Mepartricin (SPA-S-160 enteric-coated tablets) fat-lowering effect was evaluated in 20 patients with lipids disorders of various type. The cross-over trial was carried out with clofibrate as reference drug. Posology consisted, in both treatments, of 3 tablets/die. All subjects received each drug for a 30-day period, with a drug-free interval of 30 days. The results proved positive for both drugs but mepartricin showed a better therapeutical index. Local and systemic tolerance was good for both drugs even though the transaminases values were found to be sensibly higher after the therapeutic cycle with clofibrate.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008613:Mepartricin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011090:Polyenes / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D011090:Polyenes; D014280:Triglycerides; D008613:Mepartricin; D002784:Cholesterol; D002994:Clofibrate
Correzione degli stati iperdislipidemici mediante una sostanza a struttura polienica. Ricerca clinica controllata.